Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Timing of measurements and outline of primary and secondary outcome measures

From: The effect of glucosamine sulphate on osteoarthritis: design of a long-term randomised clinical trial [ISRCTN54513166]

  0 m
B.A.
3 m
Q
6 m
Visit
9 m
Q
12 m
Visit
15 m
Q
18 m
Visit
21 m
Q
24 m
F.A.
Primary outcome measures          
Joint space width x         x
Pain score (WOMAC) x         x
Function score (WOMAC) x         x
Secondary outcome measures          
Subchondral bone quality x         x
Stiffness score (WOMAC) x x x x x x x x x
Quality of life (EuroQol EQ-5D) x x x x x x x x x
Medical consumption x x x x x x x x x
Side effects   x x x x x x x x
CTX-II x   x   x   x   x
Possible confounders/Effect modifiers          
Type of OA (localised – generalised) x         
Radiological severity x         x
Joint function x         x
Age x         
Gender x         
Activity level x x x x x x x x x
Co-interventions x x x x x x x x x
Compliance (BMQ)   x x x x x x x x
Compliance (pill count)    x   x   x   x
  1. Note: 0 m: 0 month of follow up, 3 m: 3 months of follow up etc. B.A.: baseline assessment. Visit: 6 monthly visit. F.A.: final assessment